U.S. Packaging Stock News

If you are wondering whether Royalty Pharma's current share price still makes sense after a strong run, the key is to look closely at what the market might be pricing in. The stock last closed at US$49.48, with returns of 1.4% over 7 days, 9.1% over 30 days, 27.3% year to date and 57.4% over the past year, which naturally raises questions about how expectations and risk perceptions are being reflected in the price. Recent attention around Royalty Pharma has largely centered on its role as a...

Sonic Automotive has acquired five additional Harley-Davidson dealerships across the US, expanding its presence in the motorcycle retail market. Harley-Davidson has introduced a new global brand platform called "RIDE", including a refreshed visual identity and a large-scale marketing campaign. For investors watching NYSE:HOG, these developments come as the stock trades at $24.27, with a 38.1% return over the past 30 days and 17.6% year to date. Over a longer horizon, a 30.1% decline over...

FTAI Aviation (NasdaqGS:FTAI) has launched FTAI Power, a new platform focused on repurposing retired jet engines for AI data centers. The company also announced a second structured aircraft acquisition program, expanding its approach to sourcing and financing aircraft assets. These moves signal a wider set of opportunities for FTAI Aviation beyond traditional aviation leasing and engine services. FTAI Aviation operates in aircraft leasing and engine management, and now it is stepping...

Wondering if FirstCash Holdings at around US$208 a share still offers value, or if most of the upside is already priced in. The stock has returned 2.6% over the last week, 8.3% over the past month, 32.7% year to date and 73.0% over the last year, with 3 year and 5 year returns of 125.1% and 207.7% respectively. Recent coverage has focused on FirstCash Holdings' role in consumer finance and how its pawn and retail operations fit into broader credit conditions. This helps frame expectations...

AMC Robotics (AMCI) has just wrapped up FY 2025 with Q4 revenue of US$1.3 million and a basic EPS loss of US$0.52, while trailing twelve month figures show revenue of US$6.0 million and a basic EPS loss of US$1.36 alongside a reported 41.4% revenue decline over the year. Over the past few reported periods, quarterly revenue has ranged from US$1.3 million to US$3.2 million and basic EPS has swung between a profit of US$0.15 and a loss of US$0.52, underscoring how volatile the earnings line has...

IDEAYA Biosciences (NasdaqGS:IDYA) has entered a clinical collaboration with AstraZeneca to study IDE849, a DLL3 TOP1 antibody drug conjugate. The program will evaluate IDE849 in combination with Imfinzi in extensive stage small cell lung cancer and other DLL3 upregulated tumors. For readers tracking IDEAYA mainly through its uveal melanoma drug darovasertib, this collaboration with AstraZeneca broadens the story. The company, trading at $31.83, has delivered a 70.9% return over the past...

If you are wondering whether Calix at around US$49.58 still offers value or is starting to look stretched, the key is to look closely at what you are paying for each dollar of its future potential. The share price performance is mixed, with a 1.6% gain over the last 7 days, a 1.5% decline over 30 days, a 7.5% decline year to date, and a 31.8% return over the past year. These shifts can change how the market views both risk and opportunity. Investors have been reacting to ongoing industry...

If you are wondering whether Semtech's share price still reflects good value after a strong run, it helps to step back and look at what the current valuation is really pricing in. The stock last closed at US$103.48, with returns of 14.8% over 7 days, 40.6% over 30 days, 37.5% year to date and 319.1% over the past year. Any view on value now needs to factor in that kind of move. Recent news coverage has focused on Semtech's position within the broader semiconductor space and how investors are...

JBT Marel (NYSE:JBTM) is bringing its Wenger and Extru-Tech brands together for the first time at Petfood Forum 2026. The combined presence will highlight solutions for minimally processed, nutrient-dense pet food manufacturing. The move showcases new equipment offerings and closer alignment across JBT Marel’s pet food processing portfolio. For investors tracking NYSE:JBTM, this joint showcase comes with the shares at $132.63 and a 1 year return of 40.4%. The stock has also recorded a 30.8%...

Columbia Financial (CLBK) opened 2026 with Q1 revenue of US$66.2 million and basic EPS of US$0.13, anchored by net income of US$13.1 million. This puts fresh numbers behind the company’s recent return to profitability. The business has seen revenue move from US$55.9 million and EPS of US$0.09 in Q1 2025 to US$66.2 million and EPS of US$0.13 in Q1 2026, with trailing twelve month EPS at US$0.55 as the earnings base rebuilds. With a Q1 net interest margin of 2.42% and a cost to income ratio of...

CoastalSouth Bancshares (COSO) opened 2026 with Q1 total revenue of US$21.3 million and basic EPS of US$0.53, supported by net income of US$6.3 million. Over recent quarters, total revenue has moved from US$18.0 million in Q1 2025 to US$21.3 million in Q1 2026, while quarterly EPS has ranged from US$0.49 to US$0.60 across that period. This provides a clearer view of how the income statement is scaling. With a trailing net profit margin of 31.6% holding steady and a net interest margin of...

CNB Financial (CCNE) has just reported Q1 2026 results, with revenue of about US$82.3 million and basic EPS of US$0.88 setting the tone for the quarter, backed by trailing twelve month revenue of US$300.3 million and EPS of US$2.87. Over recent periods the company has seen revenue move from US$56.4 million in Q4 2024 to US$55.4 million in Q1 2025, then to US$82.3 million in Q1 2026. Quarterly EPS shifted from US$0.66 to US$0.50 and now US$0.88, giving investors a clearer view of how the...

Republic Services (NYSE:RSG) has opened an upgraded Peabody Recycling Center in Massachusetts. The facility features advanced AI powered technology aimed at improving recycling efficiency and processing capacity. The revamped site supports regional waste reduction efforts and reflects the company’s focus on technology driven operations. For investors tracking NYSE:RSG, this move fits squarely within Republic Services’ core role as a recycling and waste management operator. The company is...

Tractor Supply (TSCO) opened 2026 with Q1 revenue of US$3.6b and basic EPS of US$0.31, alongside net income of US$164.5m, setting the tone for how the year is starting to shape up. The company reported revenue of US$3.5b and EPS of US$0.34 in Q1 2025, compared with US$3.6b and EPS of US$0.31 in Q1 2026. Trailing twelve month revenue sits at US$15.6b and EPS at US$2.05, giving you a clearer read on how margins are holding up through different seasons. See our full analysis for Tractor...

Alaska Air Group (ALK) has opened 2026 with Q1 revenue of US$3.3b and a basic EPS loss of US$1.69, compared with a trailing twelve month basic EPS of US$0.63 on revenue of US$14.4b that produced net income of US$73m. Over recent quarters, revenue has moved from US$3.1b in Q1 2025 to US$3.6b in Q4 2025 before landing at US$3.3b in the latest period. Quarterly EPS has swung from a loss of US$1.35 in Q1 2025 to a profit of US$1.45 in Q2 2025 and back to a loss in Q1 2026, leaving investors...

Why the AACR data on rinzimetostat is on investors’ radar ORIC Pharmaceuticals (ORIC) shares are in focus after the company highlighted new preclinical data for rinzimetostat at the 2026 AACR Annual Meeting, centered on prostate cancer models that include treatment resistant disease. See our latest analysis for ORIC Pharmaceuticals. ORIC’s latest AACR posters on rinzimetostat arrive after a strong year to date, with a 33.29% year to date share price return and a 123.61% 1 year total...

Gogo Inc. ( NASDAQ:GOGO ), is not the largest company out there, but it received a lot of attention from a substantial...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Investors may be considering whether Universal Health Services offers good value at its current share price, or whether the recent share price move has already reflected much of the opportunity. The stock last closed at US$179.72, with a 1.9% decline over 7 days, a 3.3% decline over 30 days, an 18.3% decline year to date, and a 14.9% gain over the past year. Recent coverage has focused on Universal Health Services as a major player in US healthcare services, with ongoing attention on how...

Ocular Therapeutix (NasdaqGM:OCUL) released new 52-week post hoc Phase 3 data for AXPAXLI in wet age-related macular degeneration. The SOL-1 trial data indicated better durability, strong sustained disease control, and safety outcomes compared to aflibercept. The company presented the findings at a major ophthalmology conference and plans to seek FDA approval with a single pivotal Phase 3 trial. Ocular Therapeutix focuses on therapies for eye diseases, with AXPAXLI (OTX TKI) aimed at...

The United States market has experienced a notable upswing, climbing 3.6% in the last week and rising 39% over the past year, with earnings projected to grow by 16% annually. In this environment, identifying stocks that may be trading below their estimated intrinsic value can present compelling opportunities for investors seeking to capitalize on potential market inefficiencies.

Agree Realty (NYSE:ADC) has approved increases to both its common and preferred dividends following board authorization. The updated payouts represent a change in the company’s dividend policy that is material for existing and prospective shareholders. These actions follow a period in which the stock has returned 10.3% year to date and 38.7% over 5 years, with the latest close at $79.56. For investors watching dividend income, Agree Realty’s new board-approved increases to both common and...

Last week, First Watch Restaurant Group, Inc.'s (NASDAQ:FWRG) stock jumped 16%, but insiders who sold US$4.6m worth of...

One thing we could say about the analysts on Monte Rosa Therapeutics, Inc. ( NASDAQ:GLUE ) - they aren't optimistic...